# Sermorelin vs Ipamorelin: How a GHRH Analogue and a GHRP Differ

> Sermorelin vs ipamorelin: sermorelin is a GHRH analogue on the GHRH receptor; ipamorelin is a GHRP on the separate ghrelin/GHS receptor — two distinct mechanisms, compared and cited.

Two GH secretagogues, two different receptors. Sermorelin works at the GHRH receptor; ipamorelin works at the separate ghrelin/GHS receptor. The mechanism contrast, read straight.

## The short version

Sermorelin vs ipamorelin is a comparison of two different doors into the same room. Both make the pituitary release growth hormone, but they push different buttons. Sermorelin is a GHRH analogue — it copies the brain's natural "make GH" signal and works at the GHRH receptor. Ipamorelin is a GHRP (a growth-hormone-releasing peptide) — it works at a separate receptor, the ghrelin receptor, and was described as the first selective GH releaser, raising growth hormone without much effect on stress or prolactin hormones. Different mechanisms, often studied together.

## Two receptors, two mechanisms

The core of sermorelin vs ipamorelin is receptor identity. Sermorelin is GHRH(1-29), a GHRH analogue that binds the GHRH receptor (GHRH-R) on pituitary somatotrophs and drives the cAMP/PKA pathway to release the body's own GH [15]. Ipamorelin belongs to the GHRP class — growth-hormone-releasing peptides that act on the ghrelin receptor (the growth-hormone-secretagogue receptor, GHS-R), a different protein entirely [15].

That distinction is why ipamorelin was characterized as the first *selective* GH secretagogue: it releases GH without significant effects on ACTH/cortisol or prolactin — a cleaner profile than earlier GHRPs, and a different mechanism from a GHRH analogue [15]. Sermorelin's selectivity sits elsewhere: because it acts through the native GHRH pathway, it preserves the somatostatin and IGF-1 feedback that shapes pulsatile GH release [4].

## Why the two are studied together

Because the two receptors are independent, a GHRH analogue and a GHRP can act in a complementary, even synergistic, way on pituitary GH release. In older adults with low GH/IGF-1, low-dose GHRP-2 (a GHRP cousin of ipamorelin) augmented the GH response to GHRH(1-44)NH2, and chronic GHRP-2 for 30 days raised pulsatile GH and serum IGF-1 within 24 hours and kept it elevated [11].

The magnitude of that combined response is governed by non-peptide factors. Under a sex-steroid clamp, abdominal visceral fat, IGF-1 and IGFBP-3 together explained 60% of the variability in GHRH-GHRP synergy in men — IGF-1 positively, visceral fat negatively [10]. These are studied combinations in the research literature, not a human dosing recommendation.

## Half-life and the practical contrast

Native sermorelin is short-acting — a plasma half-life on the order of ~10-12 minutes, though a single dose keeps serum GH elevated for about 3 hours [3]. GHRPs likewise act as short-pulse secretagogues. The practical reading is that neither native sermorelin nor a short GHRP provides multi-day stimulation on its own; that property belongs to the DAC-extended GHRH analogues covered in [sermorelin vs CJC-1295](/sermorelin-vs-cjc-1295).

For a fuller view of [sermorelin and the GH/IGF-1 axis](/research), and the side-effect record for GHRH(1-29), see the research page. Nothing here is a protocol; it is a mechanism comparison drawn from the published literature.

## Sermorelin vs ipamorelin: what is the difference?

Sermorelin is a GHRH analogue acting on the GHRH receptor; ipamorelin is a GHRP/secretagogue acting on the separate ghrelin (GHS) receptor [15]. Ipamorelin was characterized as the first selective GH secretagogue, releasing GH without significant effects on ACTH/cortisol or prolactin — a different mechanism from a GHRH analogue [15]. They are often studied in combination because the two receptor pathways are complementary [11].

---

A green-phosphor terminal reading of the sermorelin record — each GHRH(1-29) figure logged to its study, the ~10-12-minute half-life that motivates the longer-acting analogues surfaced first, the formerly-approved-now-compounded history stated as filed, and the body-composition evidence marked as tesamorelin where it belongs; the 'order' here is a command at a prompt, never a checkout, and nothing on this console is dosed, dispensed, or sold.